Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-03-18

FDA Approved: ZIPRASIDONE HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approves BluePoint Laboratories' supplemental application for ZIPRASIDONE HYDROCHLORIDE, a generic form of ziprasidone, indicating approval of a supplement …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZIPRASIDONE HYDROCHLORIDE (Ziprasidone hydrochloride)

Snippet

SUPPL AP for ZIPRASIDONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE)